Hybio Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Equivalents	150.79	100.72	94.87	344.01	106.26	138.92
Trading Asset Securities	-	1.23	1.11	-	160.57	477.68
Cash & Short-Term Investments	150.79	101.95	95.97	344.01	266.83	616.6
Cash Growth	-59.61%	6.23%	-72.10%	28.92%	-56.73%	36.52%
Accounts Receivable	150.41	131.43	99.87	145.42	318.07	282.64
Other Receivables	7.29	7.24	11.15	22.44	11.88	54.39
Receivables	157.71	138.67	111.02	167.87	329.95	337.03
Inventory	402.93	261.38	238.63	152.59	189.96	157.14
Prepaid Expenses	-	8.84	10.29	2.56	0.19	-
Other Current Assets	26.64	12.72	7.14	16.61	25.39	44.31
Total Current Assets	738.06	523.56	463.05	683.64	812.32	1,155
Property, Plant & Equipment	1,861	1,745	1,674	1,734	1,942	1,993
Long-Term Investments	15.75	81.19	89.11	105.85	131.11	139.74
Goodwill	-	-	-	-	-	0.19
Other Intangible Assets	329.15	262.85	293.41	222.5	265.05	263.56
Long-Term Deferred Tax Assets	40.35	41.88	43.76	39.55	38.01	34.07
Long-Term Deferred Charges	127.97	233.07	175.99	217.81	250.41	228.02
Other Long-Term Assets	440.06	266.29	268.53	273.73	172.5	93.2
Total Assets	3,552	3,154	3,008	3,277	3,611	3,906

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Accounts Payable	363.66	261.97	218.26	108.5	129.05	90.73
Accrued Expenses	15.94	68.59	78.5	100.92	49.16	72.78
Short-Term Debt	809.95	1,033	638.99	634.21	320.92	338.23
Current Portion of Long-Term Debt	156.36	249.16	293.53	453.18	456.11	63.05
Current Portion of Leases	-	0.82	0.82	0.21	2.88	11.06
Current Income Taxes Payable	8.82	7.97	6.72	2.84	-	0.32
Current Unearned Revenue	168.14	108.21	130.55	55.33	62.69	48.79
Other Current Liabilities	79.7	51.68	57.17	68.26	127.14	118.86
Total Current Liabilities	1,603	1,782	1,425	1,423	1,148	743.82
Long-Term Debt	947.41	626.9	864.58	942.05	1,026	1,377
Long-Term Unearned Revenue	114.1	97.69	106.91	101.19	118.62	124.73
Long-Term Deferred Tax Liabilities	17.23	15.41	8.84	5.01	4.2	0.81
Other Long-Term Liabilities	5.82	2.32	6.29	22.29	17.06	12.3
Total Liabilities	2,687	2,524	2,411	2,494	2,314	2,258

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Common Stock	883.24	883.24	883.24	883.24	916.93	916.93
Additional Paid-In Capital	1,448	1,448	1,448	1,463	1,748	1,700
Retained Earnings	-1,520	-1,757	-1,794	-1,627	-1,113	-740
Treasury Stock	-	-	-	-	-318.66	-318.66
Comprehensive Income & Other	39.5	39.97	41.22	39.27	37.5	26.51
Total Common Equity	850.24	613.95	578.63	758.8	1,271	1,585
Minority Interest	14.92	15.98	18.42	24.41	26.3	63.31
Shareholders' Equity	865.16	629.93	597.05	783.21	1,297	1,648
Total Liabilities & Equity	3,552	3,154	3,008	3,277	3,611	3,906

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Total Debt	1,914	1,910	1,798	2,030	1,806	1,789
Net Cash (Debt)	-1,763	-1,808	-1,702	-1,686	-1,540	-1,173
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-1.96	-1.98	-1.96	-1.90	-1.74	-1.14
Filing Date Shares Outstanding	840.38	883.24	883.24	883.24	883.24	883.24
Total Common Shares Outstanding	840.38	883.24	883.24	883.24	883.24	883.24
Working Capital	-864.52	-1,258	-961.51	-739.8	-335.63	411.26
Book Value Per Share	1.01	0.70	0.66	0.86	1.44	1.79
Tangible Book Value	521.09	351.1	285.21	536.31	1,006	1,321
Tangible Book Value Per Share	0.62	0.40	0.32	0.61	1.14	1.50
Buildings	-	-	173.42	1,560	1,537	1,058
Machinery	-	1,138	896.3	832.92	774.95	769.85
Construction In Progress	-	136.08	37.11	67.32	153.99	699.74